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Routine versus clinically driven laboratory monitoring 
and ﬁ rst-line antiretroviral therapy strategies in African 
children with HIV (ARROW): a 5-year open-label 
randomised factorial trial
ARROW Trial team*
Summary 
Background No trials have investigated routine laboratory monitoring for children with HIV, nor four-drug induction 
strategies to increase durability of ﬁ rst-line antiretroviral therapy (ART). 
Methods In this open-label parallel-group trial, Ugandan and Zimbabwean children or adolescents with HIV, aged 
3 months to 17 years and eligible for ART, were randomly assigned in a factorial design. Randomisation was to either 
clinically driven monitoring or routine laboratory and clinical monitoring for toxicity (haematology and biochemistry) 
and eﬃ  cacy (CD4 cell counts; non-inferiority monitoring randomisation); and simultaneously to standard three-drug 
or to four-drug induction ﬁ rst-line ART, in three groups: three-drug treatment (non-nucleoside reverse transcriptase 
inhibitor [NNRTI], lamivudine, abacavir; group A) versus four-drug induction (NNRTI, lamivudine, abacavir, 
zidovudine; groups B and C), decreasing after week 36 to three-drug NNRTI, lamivudine, plus abacavir (group B) or 
lamivudine, abacavir, plus zidovudine (group C; superiority ART-strategy randomisation). For patients assigned to 
routine laboratory monitoring, results were returned every 12 weeks to clinicians; for clinically driven monitoring, 
toxicity results were only returned for requested clinical reasons or if grade 4. Children switched to second-line ART 
for WHO stage 3 or 4 events or (routine laboratory monitoring only) age-dependent WHO CD4 criteria. Randomisation 
used computer-generated sequentially numbered tables incorporated securely within the database. Primary eﬃ  cacy 
endpoints were new WHO stage 4 events or death for monitoring and change in CD4 percentage at 72 and 144 weeks 
for ART-strategy randomisations; the co-primary toxicity endpoint was grade 3 or 4 adverse events. Analysis was by 
intention to treat. This trial is registered, ISRCTN24791884.
Findings 1206 children were randomly assigned to clinically driven (n=606) versus routine laboratory monitoring 
(n=600), and groups A (n=397), B (n=404), and C (n=405). 47 (8%) children on clinically driven monitoring versus 
39 (7%) on routine laboratory monitoring had a new WHO stage 4 event or died (hazard ratio [HR] 1·13, 95% CI 
0·73–1·73, p=0·59; non-inferiority criterion met). However, in years 2–5, rates were higher in children on clinically 
driven monitoring (1·3 vs 0·4 per 100 child-years, diﬀ erence 0·99, 0·37–1·60, p=0·002). One or more grade 3 or 4 
adverse events occurred in 283 (47%) children on clinically driven versus 282 (47%) on routine laboratory monitoring 
(HR 0·98, 0·83–1·16, p=0·83). Mean CD4 percentage change did not diﬀ er between ART groups at week 72 (16·5% 
[SD 8·6] vs 17·1% [8·5] vs 17·3% [8·0], p=0·33) or week 144 (p=0·69), but four-drug groups (B, C) were superior to 
three-drug group A at week 36 (12·4% [7·2] vs 14·1% [7·1] vs 14·6% [7·3], p<0·0001). Excess grade 3 or 4 events in 
groups B (one or more events reported by 157 [40%] children in A, 190 [47%] in B; HR [B:A] 1·32, 1·07–1·63) and C 
(218 [54%] children in C; HR [C:A] 1·58, 1·29–1·94; global p=0·0001) were driven by asymptomatic neutropenia in 
zidovudine-containing groups (B, C; 86 group A, 133 group B, 184 group C), but resulted in drug substitutions in only 
zero versus two versus four children, respectively. 
Interpretation NNRTI plus NRTI-based three-drug or four-drug ART can be given across childhood without routine 
toxicity monitoring; CD4 monitoring provided clinical beneﬁ t after the ﬁ rst year on ART, but event rates were very low 
and long-term survival high, suggesting ART rollout should take priority. CD4 beneﬁ ts from four-drug induction 
were not durable, but three-NRTI long-term maintenance was immunologically and clinically similar to NNRTI-
based ART and could be valuable during tuberculosis co-treatment.
Funding UK Medical Research Council, the UK Department for International Development; drugs donated and viral 
load assays funded by ViiV Healthcare and GlaxoSmithKline.
Introduction
In high-income countries, routine laboratory tests are 
done (typically every 3–4 months) to monitor eﬃ  cacy 
(HIV viral load, CD4 counts) and toxicity (haematology 
or biochemistry panels) in patients with HIV on 
antiretroviral therapy (ART). Although not mandated 
when public health ART rollout started,1 the extent to 
which HIV treatment programmes in resource-limited 
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settings should provide routine laboratory monitoring 
versus focus resources on expanding ART access for 
the many in need, remains an ongoing debate, 
particularly relevant with slowing growth in health 
assistance for resource-limited countries in the current 
economic crisis.2 
90% of children with HIV live in sub-Saharan Africa; 
in 2011, only about 28% of those needing ART were 
receiving it.3 Infrastructure, personnel, and supply chain 
constraints all aﬀ ect the ability to monitor, and tests for 
detecting toxicity and measuring eﬃ  cacy are generally 
unavailable, particularly at low-level facilities.4 Trials in 
adults have compared routine laboratory with clinical 
monitoring on ART.5–8 These showed no beneﬁ t from 
routine toxicity monitoring,5 small but signiﬁ cant 
beneﬁ ts from CD4 monitoring,5,8 and no signiﬁ cant 
additional beneﬁ t of viral load over CD4 monitoring.6,8 No 
trials have evaluated monitoring strategies in children on 
ART; results in adults might not be generalisable because 
of diﬀ erences in frequency of ART toxicity, predictive 
value of CD4s,9,10 and the clinical spectrum of paediatric 
HIV and its comorbidities, particularly in Africa.11
Children with HIV start ART early and will need to 
take treatment for longer than adults. Challenges in 
treatment of young children, in whom viral loads are 
higher, pharmacokinetics more variable, and adherence 
more challenging, might account for the lower virological 
suppression rates in children compared with adults in 
similar calendar periods.12,13 However, four-drug combin-
ations (generally three nucleoside reverse transcriptase 
inhibitors [NRTIs] plus one non-nucleoside reverse 
transcriptase inhibitor [NNRTI]) have been reported to 
show superior virological and immunological responses 
compared with three-drug ART (two NRTIs plus one 
NNRTI or protease inhibitor) in an observational study 
in infants.14 Whether addition of one drug for a short 
period in an induction-maintenance approach might 
have beneﬁ ts across childhood is unknown. A key 
advantage might be more rapid reduction of high viral 
loads in ART-naive children, which could have long-term 
beneﬁ ts. A triple NRTI regimen after four-drug NRTI 
plus NNRTI induction also avoids challenges of manag-
ing interactions with antituberculosis drugs, particularly 
for young children unable to take efavirenz. 
We therefore undertook the ﬁ rst paediatric trial 
(AntiRetroviral Research fOr Watoto [ARROW]) to 
evaluate the long-term eﬀ ect of routine eﬃ  cacy and 
toxicity monitoring and diﬀ erent ﬁ rst-line ART strategies 
in a factorial design in African children. 
Methods
Trial design
ARROW was an open-label randomised parallel-group 
trial in untreated (except for ART to prevent mother-
to-child-transmission) children or adolescents (aged 
3 months to 17 years) with HIV who met WHO 2006 
criteria for ART initiation15 from three centres in Uganda 
(Joint Clinical Research Centre, Kampala; Baylor-
Uganda, Mulago; MRC/UVRI Uganda Research Unit on 
AIDS, Entebbe), and one in Zimbabwe (University of 
Zimbabwe, Harare). Children with acute infections, on 
drugs contraindicated with ART, unlikely to adhere or to 
attend regularly, with laboratory abnormalities contra-
indicating ART, pregnant or breastfeeding, or perinatally 
exposed to ART (if <6 months old) were excluded. 
Participants were randomly assigned (1:1) to clinically 
driven monitoring versus routine laboratory plus clinical 
monitoring for toxicity (haematology and biochemistry) 
and eﬃ  cacy (CD4). Children were also randomly 
assigned (1:1:1) in a factorial design to three approaches 
for ﬁ rst-line ART: open-label lamivudine, abacavir, plus 
NNRTI continuously (group A, control); induction-
maintenance with four-drug lamivudine, abacavir, 
NNRTI, plus zidovudine for 36 weeks, then lamivu-
dine, abacavir, plus NNRTI (group B); or induction-
maintenance with lamivudine, abacavir, NNRTI, plus 
zidovudine for 36 weeks, then lamivudine, abacavir, plus 
zidovudine (group C). HLA testing was not done. HIV 
viral loads were done retrospectively on stored samples. 
The hypothesis was that clinically driven monitoring 
would result in similar outcomes to routine labora-
tory monitoring (non-inferiority) and that four-drug 
induction-maintenance would have greater eﬃ  cacy than 
would standard three-drug ART. The NNRTI (nevirapine 
or efavirenz) was chosen by clinicians according to local 
availability and age. Caregivers gave written informed 
consent; older children (8–17 years) aware of their HIV 
status also gave assent or consent following national 
guidelines. The trial was approved by research ethics 
committees in Uganda, Zimbabwe, and the UK.
Randomisation and masking
Both factorial randomisations were stratiﬁ ed by centre 
and age (<7, 7–12, ≥13 years). The computer-generated 
sequentially numbered randomisation list (with variable 
block sizes) containing both allocations was pre-
prepared by the trial statistician and incorporated within 
the secure database at each trial centre, connected to but 
not located within each clinical centre, allowing trial 
managers to access the next number, but not the whole 
list. Randomisation was undertaken by clinicians phon-
ing the local trials centre. Once randomised, allocation 
was open—ie, physicians and carers were aware of 
group assignment.
Procedures 
All participants were examined by a doctor and had 
routine full blood count with white cell diﬀ erential, 
lymphocyte subsets (CD4, CD8), biochemistry tests 
(bilirubin, urea, creatinine, aspartate aminotransferase, 
alanine aminotransferase) at screening, randomisation 
(lymphocytes only), weeks 4, 8, and 12, then every 
12 weeks. Screening results were used to assess eligibility. 
All subsequent results for participants assigned to 
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routine laboratory monitoring were returned to clin-
icians, whereas results at and after randomisation for 
participants allocated clinically driven monitoring were 
only returned if requested for clinical management 
(authorised by centre project leaders); haemoglobin 
results at week 8 were automatically returned on the 
basis of early anaemia in DART,16 as were grade 4 
laboratory toxicities (protocol safety criteria; grades 
deﬁ ned17 apart from neutrophils18). Total lymphocytes 
and CD4 tests were never returned for participants on 
clinically driven monitoring, but for all children other 
investigations could be requested and concomitant drugs 
prescribed, as clinically indicated. 
All children received ART as syrups or tablets dosed 
according to WHO weight-band tables.19–21 Children were 
reviewed every 4–6 weeks by a nurse using a standard 
symptom checklist. Antiretroviral drugs could be sub-
stituted, preferably within class, after adverse events. 
During four-drug induction, a drug could be dropped 
because of toxicity or drug interactions with anti-
tuberculosis treatment. Switching to second-line ART 
(including a ritonavir-boosted protease inhibitor) was 
based on clinical criteria in all participants (new or 
recurrent WHO stage 4 event;15 or WHO stage 3 event or 
events at clinician discretion, particularly if recurrent or 
persistent), or on laboratory criteria for routine laboratory 
monitoring (conﬁ rmed on-ART CD4 of <15% at age 
1–2 years, <10% at 3–4 years, <100 cells/mL at ≥5 years). 
See appendix for further details.
Co-primary endpoints for the monitoring random-
isation were progression to new WHO stage 4 event or 
death (eﬃ  cacy), and grade 3 or 4 adverse events not 
solely related to HIV (safety). Co-primary endpoints for 
the ART-strategy randomisation were change in CD4 
percen tage from randomisation to 72 and 144 weeks 
(eﬃ  cacy) and grade 3 or 4 adverse events (safety). 
Secondary endpoints for both randomisations (if not co-
primary) were: mortality; new (or new or recurrent) 
WHO stage 4 event or death; new (or new or recurrent) 
WHO stage 3 or 4 event or death; grade 3 or 4 adverse 
events deﬁ nitely, probably, or uncertainly ART-related; 
serious adverse events22 not solely HIV-related; ART-
modifying adverse events; admissions to hospital; 
height, weight, and body-mass index for age; CD4; 
number and class of anti retrovirals received; switch to 
second-line regimen; adherence; viral load and 
resistance (done retrospectively; see appendix). All WHO 
stage 3 or 4 events, deaths, and serious adverse events 
were reviewed against prespeciﬁ ed criteria by an end-
point review committee with an independent chair and 
members, masked to randomised allocations.
Statistical analysis
1200 children followed up for 3·5–5·0 years with less 
than 10% loss to follow-up provided 90% power to 
establish that clinically driven monitoring was not 
inferior to routine laboratory monitoring on the primary 
eﬃ  cacy outcome, deﬁ ned as the upper 95% conﬁ dence 
limit for the diﬀ erence (clinically driven minus routine 
laboratory monitoring) in rate of ﬁ rst new WHO stage 4 
event or deaths per 100 child-years being no greater than 
1·6 per 100 child-years (assumed rate for routine 
laboratory monitoring of 2·5 per 100 child-years). For the 
ART-strategy randomisation, 1200 children provided 
80% power to detect diﬀ erences in change in CD4 
percentage of more than 2·5% across the three groups 
(F test, two-sided α=0·05) assuming 20% missing data 
(loss to follow-up, missed visit or test) and standard 
deviation 10%.23 Interim data were reviewed annually 
by an independent data monitoring committee (four 
meetings) using the Haybittle-Peto criterion (p<0·001).
Randomised groups were compared with Kaplan-Meier 
plots, log-rank tests, and proportional hazards models, 
stratiﬁ ed by randomisation stratiﬁ cation factors (includ-
ing the other factorial) for time-to-event disease pro-
gression, ART, and adverse event outcomes, censoring at 
the earlier of trial closure or last follow-up. Categorical 
variables were compared with χ² or exact (if indicated) 
tests. Change in CD4 percentage was compared with 
normal linear regression adjusted for randomisation 
stratiﬁ cation factors. Laboratory measurements and 
adherence were compared across randomised groups 
over time with generalised estimating equations 
(indepen dent correlation; closest measurement to each 
scheduled visit within equally spaced windows). All 
comparisons were as randomised (intention-to-treat). 
Subgroups speciﬁ ed in the analysis plan were the 
factorial randomisations, time on ART, sex, age, centre, 
CD4, weight for age, randomisation year, and previous 
ART for prevention of mother-to-child transmission. 
Baseline values were those nearest to but before and 
within 42 days of randomisation. Z scores were deter-
mined with the British reference because it covers the 
full age range of ARROW children.24 All analyses were 
done with Stata 12.1. All p values are two-sided. 
This trial is registered, ISRCTN24791884.
Role of the funding sources 
The sponsor (UK Medical Research Council), other 
funders (UK Department for International Development), 
and ViiV Healthcare/GlaxoSmithKline (donated drugs; 
funded viral load assays) had no direct role in study 
design, data collection, analysis, interpretation, report 
writing, or the decision to submit for publication. The 
corresponding author had full access to all data and 
responsibility for submission for publication.
Results 
1210 children were enrolled (March 15, 2007–Nov 18, 
2008). One was randomly assigned twice at diﬀ erent 
centres (second randomisation was excluded), and three 
had major eligibility violations, leaving 600 children 
assigned to routine laboratory and 606 to clinically driven 
monitoring, and 397 to group A, 404 to group B, and 
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405 to group C (ﬁ gure 1). Baseline characteristics were 
similar across randomised groups (table 1). Median 
follow-up to planned trial closure (March 16, 2012) 
was 4·0 (IQR 3·7–4·4) years in each monitoring 
and ART-strategy group (maximum 5·0 years; total 
4685 child-years). Only 33 (3%) children (median follow-
up 150 [IQR 46–169] weeks) not known to have died were 
not seen after trial closure (ﬁ gure 1). Completeness of 
nurse visits every 4–6 weeks and doctor visits every 
12 weeks was more than 95% (46 531/48 461 nurse, 
19 088/19 765 doctor visits) and was similar in all groups. 
For children assigned to clinically driven monitoring, 
clinicians could request individual laboratory toxicity 
results from routine haematology or biochemistry panels 
for clinical reasons. Panel tests could also be requested in 
both groups at extra patient-initiated visits. However, most 
were done at routine visits (10 805 [92%] haematology and 
10 778 [94%] biochemistry; appendix). In clinically driven 
monitoring, apart from week 8 haemoglobin (returned 
per protocol), very few results were released (from 
486 [4%] panels); most commonly requested results were 
haemo globin (2%, n=265) and neutrophils (3%, n=323; 
appen dix). More additional haematology tests were 
requested during nurse visits or extra visits in routine 
laboratory than in clinically driven monitoring (p<0·0001); 
there were no signiﬁ cant diﬀ erences in requests for 
additional biochemistry tests (p=0·17) or other non-
routine (eg, electrolytes) tests (p=0·97).
At trial end, 578 (95%) children on clinically driven 
monitoring versus 565 (94%) on routine laboratory 
monitoring were still on ﬁ rst-line ART (table 2); 
330 (83%) children in group A, 356 (88%) in group B, 
and 367 (91%) in group C were still on their original 
randomised regimen. Among 151 ﬁ rst-line drug changes, 
equal numbers were due to adverse events and 
antituberculosis therapy (both 59 changes [39%]; table 2). 
Changes to ﬁ rst-line therapy occurred at rates of 3·3 per 
100 child-years in routine laboratory monitoring versus 
3·2 per 100 child-years in clinically driven monitoring 
(p=0·94); and 3·5, 3·7, and 2·6 per 100 child-years in 
groups A, B, and C, respectively (p=0·25).
30 children in group A, 20 in group B, and nine in 
group C stopped nevirapine because of starting anti-
tuberculosis treatment. Whereas in group A nevirapine 
was mainly substituted with zidovudine (<3 years) or 
efavirenz (>3 years), in the four-drug groups, about a 
third (ﬁ ve children in group B and six in C) simply 
dropped nevirapine during four-drug induction to 
continue on three NRTIs. Adverse events resulted in a 
drug being substituted or dropped in ﬁ ve children in 
group A, 28 in group B, and 26 in group C; most changes 
were zidovudine-related (16 in B, 20 in C; table 2). 
Adherence by self-reported questionnaire was similar 
in both monitoring groups: mean 6·7% (1813/26 917) 
of children on clinically driven monitoring reported 
missing doses in the past 28 days versus 6·5% 
(1683/25 935) on routine laboratory monitoring (p=0·26). 
There were small but signiﬁ cant diﬀ erences by ART 
strategy, with fewer reporting missing doses in the past 
28 days in group A through week 36 (induction period; 
7·9% [253/2966] in group A, 9·8% [326/3014] in group B, 
9·0% [295/2999] in group C; p=0·02) and overall 
1806 screened
596 not randomised
 575 protocol exclusion criteria*
   400 WHO criteria for ART not met
   61 laboratory abnormality
   45 unwilling to attend
   35 HIV negative
   16 acute opportunistic infection
   12 acute tuberculosis treatment
   6 previous ART
 21 other reason
  6 died before enrolment
  6 didn’t return
  3 declined consent
  6 other
1210 randomised
608 assigned to clinically driven 
 monitoring
602 assigned to routine laboratory 
 and clinical monitoring
A
B
1210 randomised factorially with monitoring randomisation
398 assigned to group A 406 assigned to group B 406 assigned to group C
606 analysed
 2 excluded (1 randomised 
  twice†, 1 HIV negative‡)
600 analysed
 2 excluded (both randomised 
  in error§)
606 initiated ﬁrst-line ART
 20 not known to have died and 
  last seen before study end
   13 lost to follow-up
   7 withdrew consent
 25 died before study end
397 initiated ﬁrst-line ART
  1 not per randomisation‡
 12 not known to have died and 
  last seen before study end
  1 unseen after enrolment
  9  lost to follow-up
  2 withdrew consent
 20 died before study end
404 initiated ﬁrst-line ART
  1 not per randomisation‡
 8 not known to have died and 
  last seen before study end
  5 lost to follow-up
  3 withdrew consent
 14 died before study end
405 initiated ﬁrst-line ART
   0 not per randomisation
 13 not known to have died and 
  last seen before study end
   8 lost to follow-up
   5 withdrew consent
 20 died before study end
600 initiated ﬁrst-line ART
 13 not known to have died and 
  last seen before study end
   1 unseen after enrolment
   9 lost to follow-up
   3 withdrew consent
 29 died before study end
397 analysed
 1 excluded (randomised in 
  error§)
404 analysed
 2 excluded (1 HIV negative‡, 
  1 randomised in error§)
405 analysed
 1 excluded (randomised 
  twice†)
Figure 1: Trial proﬁ le
Study ended on March 16, 2012. ART=antiretroviral therapy. *Predominant reason for ineligibility given according 
to frequency. †First randomisation included, second excluded. ‡Communication error at enrolment. §Both on 
intensive phase of tuberculosis treatment. 
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(6·1% [1059/16345], 7·3% [1302/16640], 6·5% [1135/16371], 
respectively; p<0·0001).
No child switched to second-line treatment during 
their ﬁ rst year on ART. Overall, 28 (5%) children on 
clinically driven monitoring versus 35 (6%) on routine 
laboratory monitoring switched to second-line treatment 
(hazard ratio [HR] 0·78, 95% CI 0·48–1·29, p=0·22; 
table 2; ﬁ gure 2), after median 2·8 (IQR 1·8–3·3) years 
versus 2·2 (1·5–3·0) years, respectively. All children on 
routine laboratory monitoring meeting CD4 switch 
criteria actually switched. At switch, median CD4 
percentage was 8·5% (IQR 1·5–22·5) in the clinically 
driven monitoring group and 7% (3–13) in the routine 
laboratory monitoring group; 11 children (39%) versus 
14 (40%) had CD4 percentage less than 5% and six 
children (21%) versus none had CD4 percentage 
greater than 25%, respectively. 2% of follow-up 
(40/2373 child-years) was spent on second-line treatment 
Monitoring strategy First-line ART strategy
Clinically driven 
monitoring (n=606)
Routine laboratory and 
clinical monitoring (n=600)
Group A (n=397) Group B (n=404) Group C (n=405)
Centre
Entebbe, Uganda 92 (15%) 96 (16%) 61 (15%) 61 (15%) 66 (16%)
Joint Clinical Research Centre, Kampala, Uganda 161 (27%) 157 (26%) 104 (26%) 108 (27%) 106 (26%)
Paediatric Infectious Disease Centre, Mulago, Uganda 152 (25%) 148 (25%) 101 (25%) 99 (25%) 100 (25%)
University of Zimbabwe, Harare, Zimbabwe 201 (33%) 199 (33%) 131 (33%) 136 (34%) 133 (33%)
Male 298 (49%) 298 (50%) 193 (49%) 207 (51%) 196 (48%)
Age (years) 5·9 (2·2 to 9·2) 6·0 (2·6 to 9·4) 6·1 (2·4 to 9·3) 6·2 (2·5 to 9·4) 5·7 (2·3 to 9·3)
Children younger than 3 years 197 (33%) 173 (29%) 121 (30%) 117 (29%) 132 (33%)
Vertical exposure* 605 (>99%) 594 (99%) 395 (99%) 401 (99%) 403 (>99%)
CD4
Median CD4 percentage (%) 12·5% (7·5 to 17·3) 12·0% (7·0 to 17·0) 11·7% (6·9 to 17·5) 12·0% (7·1 to 17·0) 12·5% (8·0 to 17·0)
Children with CD4 percentage <5% 92 (15%) 110 (18%) 75 (19%) 67 (17%) 60 (15%)
Median CD4 cell count† 244 (114 to 369) 237 (94 to 366) 221 (87 to 341) 242 (108 to 369) 262 (114 to 373)
WHO stage
1 13 (2%) 7 (1%) 4 (1%) 7 (2%) 9 (2%)
2 160 (26%) 174 (29%) 119 (30%) 116 (29%) 99 (24%)
3 346 (57%) 337 (56%) 217 (55%) 228 (56%) 238 (59%)
4 87 (14%) 82 (14%) 57 (14%) 53 (13%) 59 (15%)
Eligibility for ART
Clinical only 95 (16%) 96 (16%) 67 (17%) 59 (15%) 65 (16%)
Immunological only 160 (26%) 167 (28%) 114 (29%) 114 (28%) 99 (24%)
Clinical and immunological 351 (58%) 337 (56%) 216 (54%) 231 (57%) 241 (60%)
Median weight-for-age Z score‡ –2·3 (–3·4 to –1·3) –2·2 (–3·3 to –1·3) –2·3 (–3·5 to –1·3) –2·2 (–3·2 to –1·4) –2·2 (–3·4 to –1·3)
Weight-for-age Z score <–3 191 (32%) 184 (31%) 130 (33%) 119 (29%) 126 (31%)
Median height-for-age Z score‡ –2·5 (–3·4 to –1·5) –2·4 (–3·4 to –1·5) –2·4 (–3·4 to –1·5) –2·5 (–3·4 to –1·5) –2·4 (–3·3 to –1·5)
Height-for-age Z score <–3 211 (35%) 191 (32%) 139 (35%) 127 (31%) 136 (34%)
Haemoglobin (g/L) 105 (95 to 115) 106 (96 to 116) 105 (94 to 115) 107 (96 to 116) 106 (94 to 115)
Neutrophils (×1000 cells per mL) 2·0 (1·4 to 2·9) 2·1 (1·5 to 2·9) 2·0 (1·4 to 2·8) 2·2 (1·5 to 3·0) 2·0 (1·4 to 2·8)
First-line ART, abacavir plus lamivudine plus
Nevirapine 129 (21%) 125 (21%) 253 (64%) 1 (<1%) 0
Efavirenz§ 71 (12%) 72 (12%) 143 (36%) 0 0
Zidovudine plus nevirapine¶ 256 (42%) 248 (41%) 1 (<1%) 249 (62%) 254 (63%)
Zidovudine plus efavirenz¶ 150 (25%) 155 (26%) 0 154 (38%) 151 (37%)
Prophylaxis use from enrolment
Co-trimoxazole 603 (>99%) 598 (>99%) 396 (>99%) 402 (>99%) 403 (>99%)
Dapsone 3 (<1%) 0 1 (<1%) 1 (<1%) 1 (<1%)
None 0 2|| (<1%) 0 1|| (<1%) 1|| (<1%)
Data are n (%) or median (IQR). ART=antiretroviral therapy. *Seven children with missing route of HIV transmission had no evidence of HIV infection in the biological mother who was already deceased at the 
time of trial enrolment with no other evidence suggesting infection. †Age older than 5 years at enrolment. ‡Z score using UK 1990 reference24 to include full age range. §Efavirenz not licensed for children 
younger than 3 years. ¶Children initiating ART with four drugs dropped either nevirapine, efavirenz, or zidovudine at week 36 in factorial randomisation. ||Grade 2 neutropenia at enrolment: initiated 
co-trimoxazole 1 and 4 months later.
Table 1: Characteristics at randomisation
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in children on clinically driven monitoring versus 3% 
(67/2311 child-years) in those on routine laboratory 
monitoring. 26 [7%] children in group A switched to 
second-line treatment versus 17 [4%] in group B and 
20 (5%) in group C; these diﬀ erences were not signiﬁ cant 
(p=0·25; ﬁ gure 2).
There was no evidence of interaction between moni-
toring and induction-maintenance ART strategies in 
primary or secondary outcomes (heterogeneity p>0·1) 
except for WHO stage 4 events or death in the ﬁ rst year 
on ART, for which the relative diﬀ erence between 
clinically driven and routine laboratory monitoring 
varied by ﬁ rst-line ART strategy (appendix). Since most 
variation was between groups B and C, who received 
identical ART for the ﬁ rst 36 weeks, this year 1 interaction 
appeared attributable to chance in children initiating 
ART with severe immunodeﬁ ciency. 
47 (8%) children on clinically driven monitoring versus 
39 (7%) on routine laboratory monitoring had a new 
WHO stage 4 event or died (2·0 vs 1·7 per 100 child-years, 
respectively). The absolute diﬀ erence of 0·32 per 
100 child-years (95% CI –0·47 to 1·12) translated into a 
relative HR of 1·13 (95% CI 0·73–1·73, p=0·59; ﬁ gure 3). 
The upper 95% conﬁ dence limit for the absolute 
diﬀ erence was below the non-inferiority margin of 1·6. 
Although overall progression was similar, a prespeciﬁ ed 
subgroup analysis showed children on routine laboratory 
monitoring had higher event rates during the ﬁ rst 
3 months on ART and lower rates from the second year 
on ART compared with those on clinically driven 
monitoring (heterogeneity p=0·045; appendix). After 
year 1, 23 (4%) children on clinically driven monitoring 
versus six (1%) on routine laboratory monitoring had a 
ﬁ rst WHO stage 4 event or died (diﬀ erence 0·99 per 
Monitoring strategy First-line ART strategy
Clinically driven 
monitoring (n=606)
Routine laboratory and 
clinical monitoring 
(n=600)
Group A 
(n=397)
Group B 
(n=404)
Group C 
(n=405)
At end of trial or when last seen alive
Remained on ﬁ rst-line ART 578 (95%) 565 (94%) 371 (93%) 387 (96%) 385 (95%)
On randomised ﬁ rst-line ART 534 (88%) 519 (87%) 330 (83%) 356 (88%) 367 (91%)
Had switched to second-line ART 28 (5%) 35 (6%) 26 (7%) 17 (4%) 20 (5%)
For CD4 criteria, per protocol 0 17 10 3 4
For other CD4 concerns* 0 11 3 4 4
For new or recurrent WHO stage 4 event per protocol† 26 6 11 10 11
Severe failure to-thrive 15 3 5 7 6
For persistent WHO stage 3 event per protocol 2 1 2 0 1
Moderately severe failure-to-thrive 1 0 0 0 1
Ever changed a drug in ﬁ rst-line ART
All 69 (11%) 68 (11%) 46 (12%) 53 (13%) 38 (9%)
Ever changed a drug for toxicity‡ 40 (7%) 44 (7%) 19 (5%) 35 (9%) 30 (7%)
Ever substituted a drug for toxicity 27 (4%) 26 (4%) 19 (5%) 17 (4%) 17 (4%)
Ever changed a drug for tuberculosis‡ 31 (5%) 28 (5%) 30 (8%) 20 (5%) 9 (2%)
Ever substituted a drug for tuberculosis 24 (4%) 24 (4%) 30 (8%) 15 (4%) 3 (1%)
Total changes to ﬁ rst-line ART
All 75 (100%) 76 (100%) 53 (100%) 58 (100%) 40 (100%)
Total changes for toxicity 29 (39%) 30 (39%) 5 (9%) 28 (48%) 26 (65%)
Dropped zidovudine for haematological AE 11 13 0 15 9
Substituted zidovudine for haematological AE 5 5 0 1 9
Changed for rash or hypersensitivity 6 7 3 6 4
Changed for raised liver function tests 3 2 1 3 1
Changed for lipodystrophy or lipoatrophy 4 3 1 3 3
Total changes for tuberculosis 31 (41%) 28 (37%) 30 (57%) 20 (34%) 9 (23%)
Dropped nevirapine 7 4 0 5 6
Substituted nevirapine with another drug 24 24 30 15 3
Total changes for other reasons§ 15 (20%) 18 (24%) 18 (34%) 10 (17%) 5 (13%)
Data are n (% of children). ART=antiretroviral therapy. AE=adverse event. *Typically CD4 slightly higher than the WHO thresholds (conﬁ rmed on-ART CD4 <15% if age 
1–2 years, <10% if 3–4 years, <100 cells per mL if ≥5 years). †Some events that led to switching were not adjudicated to meet prespeciﬁ ed protocol criteria by the endpoint 
review committee and so were not included as primary or secondary endpoints. ‡Children randomly assigned to four-drug induction could drop one of the four original drugs 
for toxicity or other reasons, without having to substitute. §11 dispensing errors, six changes due to pregnancy, 16 other carer preference or domestic reasons. 
Table 2: ART received
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100 child-years, 95% CI 0·37–1·60, p=0·002). The most 
common WHO stage 4 events were oesophageal 
candidiasis (eight on clinically driven and ﬁ ve on routine 
laboratory monitoring) and severe unexplained failure-
to-thrive (nine on clinically driven and three on routine 
laboratory monitoring). 
25 (4%) children died in the clinically driven monitoring 
group versus 29 (5%) in the routine labora tory monitoring 
group (1·1 vs 1·3 per 100 child-years, respectively; diﬀ er-
ence –0·2 per 100 child-years, 95% CI –0·82 to 0·41; 
HR 0·84, 95% CI 0·49–1·44; p=0·45; appendix). Most 
deaths (19 clinically driven and 20 routine laboratory 
monitoring) were primarily HIV-related; only one was 
drug-related (chemotherapy plus zidovudine). Similar 
variation over time (heterogeneity p=0·03; appendix) 
was observed for deaths alone as for the combined end-
point of WHO stage 4 or death (13 deaths on clinically 
driven and 27 on routine labora tory monitoring in ﬁ rst 
year, 12 vs two subsequently; diﬀ erence 0·56 per 
100 child-years, 95% CI 0·15–0·97, with 12 of the 14 
deaths after 1 year in children aged >8 years). Progression 
to new WHO stage 3 or 4 events or death gave similar 
results (HR [clinically driven:routine laboratory moni tor-
ing] 1·00, 0·73–1·38; p=0·98; appendix). Pulmonary 
tuber culosis was the commonest WHO stage 3 event 
(25 clinically driven monitoring, 28 routine laboratory 
monitoring). Among 45 WHO stage 3 or 4 events 
reported on clinically driven monitoring and 21 on 
routine laboratory monitor ing from the second year 
onwards, 14 versus one were failure-to-thrive and 
15 versus 15 were extra pulmonary or pulmonary tuber-
culosis, highlighting the potential of weight monitoring 
to identify ﬁ rst-line CD4 failure clinically.
CD4 percentage increased throughout the ﬁ rst 3 years 
on ART before plateauing in both groups (ﬁ gure 3; 
p=0·23). Only 11 (2%) children on clinically driven 
monitoring versus two (<1%) on routine laboratory 
monitoring had CD4 less than 5% at their last visit (exact 
p=0·01; appendix). Viral load suppression was similar in 
both monitoring groups (ﬁ gure 3; global p>0·7). At the 
latest test, median 3·7 (IQR 3·0–4·1) years after ART 
initiation, 351 (77%) of 458 children on clinically driven 
monitoring versus 345 (78%) of 443 on routine laboratory 
monitoring had viral load less than 400 copies per mL 
(p=0·66), similar across ages (heterogeneity p=0·25); 
329 (72%) on clinically driven monitoring versus 
313 (71%) on routine laboratory monitoring had viral load 
less than 80 copies per mL (p=0·70). 
Weight for age and height for age did not diﬀ er 
signiﬁ cantly between groups (p=0·71, p=0·07; appen-
dix). 49 (9%) children on clinically driven monitoring 
versus 29 (5%) on routine laboratory monitoring had 
weight-for-age Z score less than –3 (approximate one 
thousandth percentile of normal UK weight) at last visit 
(global p=0·12). 
One or more grade 3 or 4 adverse events (co-primary 
endpoint) occurred in 283 (47%) children on clinically 
driven monitoring versus 282 (47%) on routine 
laboratory monitoring (HR 0·98, 95% CI 0·83–1·16, 
p=0·83; ﬁ gure 3). Of 1170 adverse events (621 clinically 
driven monitoring, 549 routine laboratory monitoring), 
810 (69%) were asymptomatic laboratory results, most 
commonly grade 3 neutropenia (171 clinically driven 
monitoring, 167 routine laboratory monitoring; appen-
dix); only 87 (7%) were deﬁ nitely, probably, or uncertainly 
ART-related (41 clinically driven monitoring, 46 routine 
laboratory monitoring). 111 (18%) children on clinically 
driven monitoring versus 109 (18%) on routine labora-
tory monitoring had one or more grade 4 adverse events 
(HR 0·99, 0·76–1·29, p=0·94). Although there was no 
diﬀ erence in grade 4 adverse events, 147 (24%) children 
on clinically driven monitoring versus 117 (20%) on 
routine laboratory monitoring had one or more serious 
adverse events (any grade; HR 1·30, 1·02–1·66, p=0·04). 
Most of the 362 serious adverse events (217 clinically 
driven, 145 routine laboratory monitoring) were malaria 
(113 clinically driven, 65 routine laboratory monitoring), 
and most (179 clinically driven, 117 routine laboratory 
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monitoring) were admissions to hospital. The excess 
malaria serious adverse events in the clinically driven 
monitoring group were mostly in children with parasite 
counts less than 500 per 200 white blood cells, or were 
not diagnostically conﬁ rmed (ﬁ gure 3). Diﬀ erences in 
time to ﬁ rst hospital admission were smaller (HR 1·18, 
0·99–1·41, p=0·07), with no diﬀ erence in duration of 
admission (median 5 [IQR 3–6] days in clinically driven 
and routine laboratory monitoring; rank-sum p=0·54). 
ART-modifying adverse events occurred in 31 (5%) 
children on clinically driven monitoring versus 32 (5%) 
on routine laboratory monitoring (HR 0·95, 0·58–1·56, 
p=0·84). The most common modiﬁ cation (14 clinically 
driven, 13 routine laboratory monitoring) was to stop 
(on four-drug regimen) or substitute zidovudine. 
There was no signiﬁ cant diﬀ erence between the three 
ART strategy randomisation groups in mean CD4 per-
cen tage change at week 72 (p=0·33) or 144 (p=0·69; 
ﬁ gure 4). However, at week 36 (when all children 
moved to three drugs), CD4 percentage responses were 
signiﬁ cantly greater in the four-drug induction groups 
(p<0·0001; ﬁ gure 4; appendix). 
Viral load suppression less than 400 copies per mL 
was similar in the three ART strategy groups at weeks 
4, 36, and 48 (p>0·4), but diﬀ ered signiﬁ cantly at weeks 
24 (p=0·009) and 144 (p=0·009; ﬁ gure 4). At week 24, 
suppression was signiﬁ cantly greater in induction 
groups receiving four drugs (285 [88%] of 324 children 
in groups B and C vs 114 [77%] of 148 in group A). By 
contrast, similarly to week 144, at the latest test 
suppression was signiﬁ cantly greater in children 
receiving two NRTIs plus an NNRTI (496 [84%] of 591 
in groups A and B vs 200 [65%] of 310 in group C). No 
signiﬁ cant diﬀ erence was seen in suppression less 
than 80 copies per mL at week 24 (p=0·41); however, 
suppression less than 80 copies per mL was signiﬁ cantly 
greater in groups A and B at week 144 and latest test 
(466 [79%] in groups A and B vs 176 [57%] in group C; 
p<0·0001). Results were similar when restricted to 
children younger than 5 years (not shown) or 3 years 
(appendix). 
There was no evidence of diﬀ erences between ART-
strategy groups in progression to new WHO stage 4 
event or death (HR [B:A] 0·89, 95% CI 0·53–1·48; HR 
[C:A] 0·91, 0·54–1·52; global p=0·89), WHO stage 3 or 4 
event or death (HR [B:A] 0·82, 0·55–1·20; HR [C:A] 
0·80, 0·54–1·17; global p=0·44), or mortality overall 
(HR [B:A] 0·66, 0·33–1·31; HR [C:A] 0·97, 0·52–1·81; 
global p=0·43; ﬁ gure 4; appendix). In particular, there 
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was no evidence that greater initial CD4 increases in 
groups B or C signiﬁ cantly reduced disease progression 
risks in the ﬁ rst year (13 deaths in group A vs nine in 
group B vs 18 in group C; 22 vs 19 vs 24 WHO stage 4 
events or deaths; 36 vs 35 vs 37 WHO stage 3 or 4 events 
or deaths). However, there was also no suggestion of 
higher event rates in group C receiving long-term three-
NRTI main tenance, despite lower long-term viral load 
suppression; if anything, fewer events occurred after 
1 year (seven deaths in group A vs ﬁ ve in group B vs two 
in group C; 18 vs 13 vs eight WHO stage 4 events or 
deaths; 37 vs 26 vs 17 WHO stage 3 or 4 events or deaths). 
There was no evidence of diﬀ erences in weight for 
age (p=0·58) or height for age (p=0·90) across ART 
strategies (appendix).
157 (40%) children in group A, 190 (47%) in group B, 
and 218 (54%) in group C had one or more grade 3 or 4 
adverse events (co-primary endpoint; HR [B:A] 1·32, 
95% CI 1·07–1·63; HR [C:A] 1·58, 1·29–1·94; global 
p=0·0001; ﬁ gure 4). The diﬀ erence was almost exclusively 
driven by excess asymptomatic neutropenia (86 vs 133 vs 
184 events; appendix). There were 15 versus 41 versus 
31 deﬁ nitely, probably, or uncertainly ART-related grade 3 
or 4 adverse events, respectively. There were no signiﬁ -
cant diﬀ erences in grade 3 or 4 anaemia or grade 4 only 
anaemia (with or without clinical symptoms; grade 3 
or 4: 38 vs 44 vs 44, respectively; grade 4: 21 vs 24 vs 25, 
respectively). There were also no signiﬁ cant diﬀ erences 
in the numbers of children with one or more grade 4 
adverse events (63 [16%] vs 81 [20%] vs 76 [19%]; HR [B:A] 
1·27, 0·91–1·76; HR [C:A] 1·20, 0·86–1·68; global 
p=0·34) or serious adverse events (87 [22%] vs 82 [20%] vs 
95 [23%]; HR [B:A] 0·92, 0·68–1·25; HR [C:A] 1·09, 
0·81–1·46; global p=0·53). 
ART-modifying adverse events occurred in eight (2%) 
children in group A versus 30 (7%) in group B and 
25 (6%) in group C (HR [B:A] 3·80, 95% CI 1·74–8·29; 
HR (C:A) 3·09, 1·39–6·85; global p=0·002; ﬁ gure 4). 
The most common modiﬁ cation (13 children in group B, 
14 in C) was to stop (on four-drug regimen) or substitute 
zido vu dine because of anaemia, even though grade 3 
and 4 anaemias occurred similarly across all three 
groups. Despite substantial numbers of grade 3 neutro-
penias, only six children (two in group B, four in 
group C) modiﬁ ed ART (zidovudine) for this reason. 
Three children substituted zidovudine because of lipo-
atrophy in group C; two children in group A and three in 
group B substituted efavirenz because of lipodystrophy 
or gynaecomastia. 
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Discussion
The DART trial5 in African adults with HIV showed that 
routine laboratory monitoring for ART side-eﬀ ects had 
no eﬀ ect on toxicity outcomes. Although routine CD4 
monitoring had signiﬁ cant beneﬁ ts on disease pro gres-
sion and mortality, absolute diﬀ erences were small.5 
Health-economic analyses suggested point-of-care CD4 
tests would need to cost less than US$3·80 for monitor-
ing every 12 weeks after the ﬁ rst year on ART to be cost-
eﬀ ective.25 Smaller adult trials of routine CD4 or viral 
load monitoring, or both, have shown similar results,6–8 
although no other trial has investigated toxicity monitor-
ing. These results provide strong reassurance that 
increasing coverage by rollout of ART to adults at lower-
level health facilities is the most rational and cost-
eﬀ ective policy at a population level, irrespective of 
provision of laboratory monitoring. 
Most health centres in resource-limited settings treat 
adults and children with HIV in the same clinics. How-
ever, results from studies in adults might not generalise to 
children who have diﬀ erent comorbidities (eg, more 
anaemia associated with malnutrition, malaria, and 
sepsis, which could aﬀ ect haematological monitoring). 
Diﬀ erences in predictive value and interpretation of CD4 
tests,9,10 faster disease progression in young children,26 and 
greater sensitivity of ART-related weight gain (which has 
reﬂ ected virological response27) could also aﬀ ect the rela-
tive beneﬁ ts of laboratory versus clinical monitoring. 
We therefore undertook the ﬁ rst paediatric trial investi-
gating ART monitoring in children with fairly advanced 
HIV disease (panel). We found that NNRTI-based regi-
mens, including WHO-recommended NRTIs, can be 
delivered safely across childhood without rou tine toxicity 
monitoring. Toxicity substitutions were infrequent, as 
previously reported;31 most were because of asymptomatic 
haematology results in children on zidovudine. Interest-
ingly, grade 3 and 4 and grade 4 anaemias occurred 
similarly across groups receiving and not receiving zido-
vu dine, both short and long term, suggesting that anaemia 
in children on ART is most likely caused by chronic HIV 
infection rather than antiretroviral drugs. Therefore, 
routine haemoglobin monitoring is likely unneces sary, 
even in children on zidovudine, and continu ation of 
zidovudine without substitution (as occurred in clinically 
driven monitoring group C children) is unlikely to result 
in harm. Further, lack of haemoglobin testing before 
initiation of ART should not prevent zidovudine use, since 
haemoglobin values increased after ART initiation. 
Crucially, we observed no evidence of interaction between 
monitoring and ART strategies on any toxicity outcome. 
We previously reported very few possible hypersensitivity 
reactions to abacavir (four [<1%] in 1206 patients32) or 
diﬃ  culties managing abacavir plus nevirapine together in 
African children. 
Importantly for programme planners, ﬁ rst-line drug 
substitutions occurred as often for tuberculosis as for 
adverse events. Tuberculosis was also by far the most 
common WHO stage 3 or 4 event. One advantage of the 
four-drug induction regimen was the ability to simply 
drop nevirapine in children starting rifampicin. The 
ongoing tuberculosis incidence illustrates the potential 
usefulness of three-NRTI regimens in children, with 91% 
randomly assigned to group C still receiving maintenance 
with lamivudine, abacavir, and zidovudine after median 
4 years. Tuberculosis remains particularly diﬃ  cult to 
manage in children younger than 3 years who cannot take 
efavirenz, because rifampicin coadministration signiﬁ -
cantly reduces nevirapine33 and lopinavir concentrations. 
Super-boosting with additional ritonavir has been 
recommended with lopinavir,34 but ritonavir is unpalatable 
and diﬃ  cult to dose.15 Substitution to three NRTIs is 
frequently used for children on NNRTI plus two NRTIs 
developing tuberculosis, but there have been concerns 
about reduced eﬃ  cacy. Viral load suppression was similar 
to standard NNRTI-based ART at 48 weeks for children 
moving to maintenance three-NRTI at 36 weeks. However, 
viral load suppression was signiﬁ cantly lower at 144 weeks, 
suggesting that long-term three-NRTI treatment would 
not be advisable (even after four-drug induction). Import-
antly, there was no evidence of immunological or clinical 
harm from roughly 15% lower viral load suppression long-
term with three NRTIs; if anything this group had fewer 
clinical events, similar to previous randomised adult 
data.35 These ﬁ ndings provide reassurance that a three-
NRTI regimen is safe for children on ART when they 
need antituberculosis co-treatment.
Overall, there was no evidence that clinically driven 
monitoring was inferior to routine laboratory monitoring 
in terms of disease progression or mortality. However, 
we found interactions with time on ART, disease 
progression or death being somewhat lower in the 
clinically driven monitoring group in the ﬁ rst year. 
Chance seems the most likely explanation, because 
management was similar with no child switching to 
second-line during the ﬁ rst year in both groups. The only 
other possible explanation is that receiving CD4, 
biochemistry, and haematology results was actually 
harm ful for children (eg, resulting in clinicians failing to 
undertake proper clinical evaluations), which seems 
implausible. From the second year, our results are 
qualitatively similar to those of the DART trial, with 
small but signiﬁ cant clinical event excesses in clinically 
driven monitoring. However, event rates were sub-
stantially lower than in DART, so the excess remained 
within the non-inferiority margin; also fewer children 
switched to second-line ART with similar proportions in 
both groups. Unlike DART, there was no evidence of 
excess switching with very low CD4 in clinically driven 
monitoring. Whereas switches in routine laboratory 
monitoring were predominantly triggered by falling 
CD4, in clinically driven monitoring most switches were 
for failure to thrive, which might be a more sensitive 
indicator of ﬁ rst-line CD4 failure than in adults and could 
be used where CD4 monitoring is unavailable. 
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Unnecessary switching at high CD4 did occur, as in 
DART, but in very few children (six on clinically driven 
monitoring and none on routine monitoring switched 
with CD4 greater than 25%). Other paediatric studies in 
which routine CD4 and viral load monitoring were used 
have also reported fairly low rates of switching from ﬁ rst-
line NNRTI-based ART over 5–6 years (eg, 8% of 
2570 Ugandan children;36 22% in the PENPACT-1 trial30). 
As expected and previously reported, most deaths were 
soon after starting ART in children with lowest pre-ART 
CD4 or weight for age.37 Irrespective of monitoring 
strategy, 5-year survival was remarkably high (96%, 
compared with 88% in DART), emphasising the 
importance of good clinical care, and availability of 
continuous ART and concomitant treatments. Loss to 
follow-up was only 2·7%, providing conﬁ dence that 
results are robust. We also observed no diﬀ erences 
between clinically driven and routine laboratory 
monitoring in CD4 or viral load responses. The only 
diﬀ erence between monitoring strategies was in serious 
adverse events, due to an excess of clinical malaria 
admissions to hospital in clinically driven monitoring. 
One limitation is that the trial allocation was of necessity 
open; lack of knowledge of CD4 in a child on clinically 
driven monitoring presenting with fever could have 
inﬂ uenced decisions about hospital admission, given the 
plausible diﬀ erential diagnosis of bacteraemia.38 
Data for viral load from the 78% of children with results 
suggest that initiation of ART with four drugs might 
signiﬁ cantly improve early viral load suppression, 
consistent with greater early CD4 responses, particularly 
in those with very low pre-ART CD4. By design all 
children moved to three drugs at 36 weeks, in view of the 
possible toxicity and costs of four-drug regimens in the 
long term. Since toxicity diﬀ erences were restricted to 
asymptomatic laboratory results with no eﬀ ect on ART 
management, results hint that a longer-term four-drug, 
three NRTIs plus one NNRTI regimen might have 
continued to provide viral load and CD4 beneﬁ ts, 
although this might not have translated into clinical 
beneﬁ t. However, viral load suppression with two NRTIs 
plus an NNRTI was fairly high, with 83% of children 
receiving an NNRTI with abacavir plus lamivudine 
throughout achieving less than 400 copies per mL long 
term, irrespective of monitoring strategy, so further gains 
from a fourth drug might be less plausible. 
Viral load suppression was similar to other trials in 
which viral load monitoring was done routinely (eg, 82% 
<400 copies per mL after median 5 years on two NRTIs 
plus an NNRTI or a protease inhibitor;30 85% of infants 
<400 copies per mL after median 5 years on two NRTI 
plsu lopinavir or ritonavir (A Violari, personal communi-
cation); 85% and 75% of children <3 years <400 copies 
per mL after 48 weeks on two NRTI plus lopinavir or 
ritonavir, or nevirapine, respectively28). This ﬁ nding 
might be partly because of superiority of abacavir (in the 
ARROW two-NRTI backbone) over zidovudine, as 
previously reported.27 Coupled with the low clinical event 
rates after 1 year in ARROW, our data suggest any 
additional beneﬁ ts from routine viral load monitoring 
are likely to be small. Although CD4 and viral load failure 
do not correlate well,39 the implications of late detection 
of viral load failure are likely to depend largely on how 
resistance evolves with persisting viral replication. In 
PENPACT-1, lamivudine and NNRTI resistance occurred 
with low-level viral load failure,30 so the consequences of 
delaying switch on these regimens until CD4 failure 
might be small; the 3-year PHPT trial in adults, which 
randomly assigned patients to routine CD4 with or 
without viral load monitoring, found no additional 
beneﬁ t from viral load, although patients in both groups 
of this trial had high viral load suppression.6
Although open allocation was an unavoidable limitation 
of the monitoring randomisation and was not undertaken 
for the ART-strategy randomisation, the endpoint review 
committee adjudicated endpoints masked to random-
isation. In a survey at ARROW exit, only four (1%) of 
561 participants on clinically driven monitoring reported 
having CD4 testing done privately; clinicians remained 
masked. One possible criticism is that all ARROW centres 
Panel: Research in context
Systematic review
We searched PubMed up to Jan 5, 2013, with search terms “HIV” AND “monitoring” AND 
(“antiretroviral therapy” OR “ART”) AND “trial”*. We identiﬁ ed three trials in adults;5,7,8 one 
further trial had been presented but not published.6 There were no trials in children. Trials in 
adults showed that clinical monitoring was safe and feasible, but CD4 monitoring to detect 
ﬁ rst-line failure provided small additional beneﬁ ts; addition of viral load to routine CD4 
monitoring provided no further beneﬁ ts. Replacement of “monitoring” with child* 
identiﬁ ed previous short-term (24 or 48 week) trials that showed three-drug protease 
inhibitor-based (lopinavir or ritonavir) ART to be superior to nevirapine-based ART in 
children younger than 3 years;28,29 however, studies in older children found similar 
responses,30 and lopinavir and ritonavir are costly and logistically challenging to administer. 
Interpretation
Routine laboratory monitoring for toxicity on non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) plus nucleoside reverse transcriptase inhibitors (NRTIs; abacavir or zidovudine plus 
lamivudine) is not needed in children, as in adults; requiring such monitoring might be a 
barrier to life-saving treatment. CD4 monitoring provided a small but signiﬁ cant reduction in 
disease progression or death after the second year on ART in children, as in adults. However, 
unlike adults, CD4 and viral load responses were very similar irrespective of CD4 versus clinical 
monitoring. Monitoring weight-gain appeared a sensitive indicator of ﬁ rst-line CD4 failure, 
and drug changes occurred as often for concurrent tuberculosis as for adverse events. 
Four-drug ART with an NNRTI plus three NRTIs provided superior short-term virological 
suppression and CD4 responses, but these beneﬁ ts were not sustained during maintenance 
three-drug ART. However, 83% of children in ARROW had viral load less than 400 copies 
per mL with abacavir, lamivudine, and a NNRTI for 3·7 years, irrespective of age, supporting 
previously reported superiority of abacavir over zidovudine.23 Three-NRTI long-term 
maintenance was clinically and immunologically similar to NNRTI-based ART, and would be 
useful during tuberculosis cotreatment. Results support an integrated approach to treatment 
of adults and children in treatment rollout. Cost and feasibility (eg, through point-of-care 
tests) of provision of CD4 monitoring are future challenges.
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had laboratories; however, the only way our results would 
not generalise to centres with lower-quality clinical care 
would be if these health-care workers were able to act 
more appropriately on routine laboratory results than in 
centres with high-quality care. This scenario seems 
unlikely since substantial CD4 variability and complexity 
around toxicity test interpretation mean that simple rules 
for acting on routine test results are unlikely ever to be 
optimum. Rather, clinicians providing the best clinical 
care are plausibly also best able to interpret and act on 
routine laboratory results. Thus although the overall risks 
of WHO events or death might be higher under poorer 
clinical care, diﬀ erences in outcomes between routine 
and clinically driven laboratory monitoring would be 
likely, if anything, to be even smaller than observed in 
ARROW. Of note, we found no evidence that small 
beneﬁ ts from CD4 monitoring varied by pre-ART CD4 or 
percentage, sug gest ing our results are robust to changes 
in ART initiation thresholds.
Toxicity monitoring has no beneﬁ t and costs money; it 
cannot therefore be cost-eﬀ ective. This fact should 
reinforce WHO guidelines that routine toxicity tests are 
not required for paediatric ART provision, as for adults. 
Formal cost-eﬀ ectiveness analysis is ongoing: given 
reduced eﬃ  cacy of CD4 monitoring compared with 
DART, CD4 monitoring every 12 weeks is unlikely to be 
cost-eﬀ ective in children overall (P Revill, personal com-
munication), although it might have some potential to 
pick up earlier failure in older children or adolescents 
concealing adherence challenges. Cost-eﬀ ectiveness 
analysis and systematic review is also planned to compare 
the induction-maintenance ART strategy with NNRTI 
and protease inhibitor-based ﬁ rst-line ART, including 
sensitivity analyses to account for increased eﬃ  cacy but 
greater cost of abacavir versus zidovudine. 
In conclusion, ARROW results should send a strong 
message to African ART programmes to accelerate ART 
rollout to children since this process currently lags woefully 
behind adults.3 The key ﬁ nding is that ART provides 
enormous beneﬁ ts to children and can be delivered safely 
with good-quality clinical care and without routine toxicity 
monitoring. For children initiating ART with severe 
immune suppression, addition of a fourth drug improves 
short-term immuno logical and virological responses; 
whether continuing a four-drug regimen longer-term 
would be advantageous remains unclear. However, 
ARROW results support short-term use of three-drug 
NRTI regimens during antituberculosis treatment in 
children already on ART. Simple point-of-care CD4 tests 
might have a future role, at least to conﬁ rm clinical need to 
switch to second-line ART, as in DART.40 In children, 
monitoring of weight gain should be emphasised as an 
important additional clinical aid for identiﬁ cation of ﬁ rst-
line failure. Laboratory tests remain important for assess-
ment of ART eligibility and for diagnosis and management 
of intercurrent infections. Mentoring of health-care 
workers to foster quality clinical care and reassurance that 
children do very well without laboratory monitoring of 
ART should energise faster and further scale-up of ART 
rollout for children with HIV in Africa. 
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